Seeking Alpha

Discovery Laboratories (DSCO -3.7%) says it will present data on two of its key products,...

Discovery Laboratories (DSCO -3.7%) says it will present data on two of its key products, Surfaxin and Afectair, at the 2012 Hot Topics in Neonatology Annual Meeting being held December 3-4 in Washington D.C. Surfaxin is the first FDA-approved synthetic, peptide-containing surfactant for the prevention of respiratory distress syndrome in premature high risk infants, while in February 2012 Afectair, a ventilator circuit that simplifies the delivery of inhaled therapies to critical care patients requiring ventilator support, was recently cleared with the FDA for marketing in the U.S.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector